SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading
medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD)
presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the
American Academy of Sleep Medicine and the Sleep Research Society. Held in
Houston, the event brought together scientific and medical experts focused on
sleep health. From exploration into the prevalence of insomnia in the Americas
to the reduction in emergency room visits among COMISA patients on PAP therapy -
the ResMed-supported research demonstrated the effectiveness and value of
positive airway pressure (PAP) treatment for OSA.
"The real-world evidence used in our clinical research continues to demonstrate
the effectiveness of PAP therapy for treating OSA," said Carlos M. Nunez, MD,
ResMed's Chief Medical Officer. "The studies presented at SLEEP 2024 expand our
understanding of patients with sleep disorders by examining critical areas such
as the effect of demographic factors like gender on sleep health. The body of
knowledge we have created and are continually expanding with research partners
who are highly respected in their fields helps ResMed and the medical community
achieve the goal of helping people live their healthiest lives."
Prevalence of Insomnia among Adults in the Americas Signals the Need to
Prioritize Sleep Health
A study
(https://academic.oup.com/sleep/article/47/Supplement_1/A173/7654658?login=false
) presented by Adam Benjafield, PhD, vice president of clinical research at
ResMed, examined the prevalence of insomnia across Northern America, Latin
America, and the Caribbean. Reviewing studies and survey data across 55
countries, the researchers extrapolated that approximately 17% of all adults in
this region have insomnia and concluded this demonstrates the importance of
sleep health as a priority within public health initiatives.
Adherence to PAP Therapy Linked to Fewer Hospital Visits Among Patients with OSA
and Comorbid Insomnia
Atul Malhotra, MD, Director of Research for Pulmonary, Critical Care and Sleep
Medicine at the University of California, San Diego, presented results of a
study
(https://academic.oup.com/sleep/article/47/Supplement_1/A230/7654682?searchresul
t=1&login=false) looking at the clinical and economic impact of treating OSA
with PAP therapy among patients with OSA and comorbid insomnia, a combination
known as COMISA. Using administrative claims data, the researchers found that
all-cause hospitalizations and emergency room visits for these patients were
lower among those who consistently adhered to PAP therapy when compared to those
who demonstrated lower PAP adherence (all-cause hospitalizations per person
0.09 vs 0.13, pÂ